問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Thoracic Medicine

Digestive System Department

更新時間：2023-09-19

吳寬澧WU, KUAN-LI
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

48Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳寬澧

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

List

36Cases

2024-01-01 - 2040-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-07-01 - 2030-01-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-03-13 - 2024-02-15

Phase I/II

Completed
An open phase 1b/2 trial to evaluate the pharmacokinetics, safety, efficacy and pharmacodynamics of PF-06801591 (PD-1 inhibitor) among participants in advanced malignancies

  • Condition/Disease

    NSCLC

  • Test Drug

    PF-06801591

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

洪仁宇
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

2021-06-01 - 2024-02-27

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2020-09-01 - 2028-12-31

Phase III

Active
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab) / JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2023-07-03 - 2026-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-05-01 - 2026-06-30

Phase II

Active
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study

  • Condition/Disease

    NSCLC

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

2020-11-01 - 2026-06-30

Phase III

Active
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372(Amivantamab)

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-11-01 - 2026-06-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab)JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting5Sites

Recruiting2Sites

Terminated1Sites

2020-09-01 - 2027-05-01

Phase I

Active
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372JNJ-73841937(lazertinib)

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB